Table 3.
Contribution of risks of bias of direct estimates to network estimates
| Comparison | Any mood episode relapse | ||
|---|---|---|---|
| Low (%) | Moderate (%) | High (%) | |
| PLB vs LIT | 0.2 | 22.5 | 77.6 |
| PLB vs VPA | 0.1 | 22.0 | 77.9 |
| PLB vs LTG | 0.1 | 8.1 | 91.7 |
| PLB vs IMP | 0.5 | 27.7 | 71.9 |
| PLB vs LIT + IMP | 1.0 | 46.2 | 53.1 |
| PLB vs ARP | 0.0 | 100.0 | 0.0 |
| PLB vs OLZ | 0.1 | 67.2 | 32.8 |
| PLB vs QTP | 0.1 | 12.0 | 87.9 |
| PLB vs RisLAI | 0.0 | 86.9 | 13.2 |
| PLB vs PAL | 0.0 | 100.0 | 0.0 |
Contributions of direct comparisons at high, moderate or low risk of bias to mixed or indirect comparisons were calculated as the sum of direct comparisons with corresponding risks of bias, weighted by the contribution matrix
ARP aripiprazole, CBZ carbamazepine, FLX fluoxetine, IMP imipramine, LIT lithium, LTG lamotrigine, OLZ olanzapine, OXC oxcarbazepine, PAL paliperidone, PLB placebo, QTP quetiapine, RisLAI risperidone long-acting injection, VPA valproate